$RNAC
Cartesian Therapeutics, Inc. Stock $rnac

$rnac Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000145368722000087 Filed on May 05, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$34.00M	$11.05M
YoY Change	207.68%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.537M	$5.200M
YoY Change	6.48%	26.83%
% of Gross Profit
Research & Development	$17.69M	$13.00M
YoY Change	36.03%	-11.68%
% of Gross Profit
Depreciation & Amortization	$100.0K	$100.0K
YoY Change	0.0%	-50.0%
% of Gross Profit
Operating Expenses	$23.23M	$18.21M
YoY Change	27.56%	-3.26%
Operating Profit	$10.77M	-$7.158M
YoY Change	-250.5%	-61.97%
Interest Expense	$707.0K	$711.0K
YoY Change	-0.56%	160.44%
% of Operating Profit	6.56%
Other Income/Expense, Net	$154.0K	$0.00
YoY Change		-100.0%
Pretax Income	$28.78M	-$24.60M
YoY Change	-216.98%	25.38%
Income Tax
% Of Pretax Income
Net Earnings	$28.78M	-$24.60M
YoY Change	-217.0%	25.37%
Net Earnings / Revenue	84.64%	-222.6%
Basic Earnings Per Share	$0.23	-$0.22
Diluted Earnings Per Share	$0.08	-$0.22
COMMON SHARES
Basic Shares Outstanding	124.2M shares	110.7M shares
Diluted Shares Outstanding	127.6M shares	110.7M shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$117.4M	$147.8M
YoY Change	-20.55%	103.6%
Cash & Equivalents	$113.4M	$125.4M
Short-Term Investments	$3.997M	$22.41M
Other Short-Term Assets	$5.420M	$7.000M
YoY Change	-22.57%	268.42%
Inventory
Prepaid Expenses
Receivables	$7.153M	$8.342M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$130.0M	$163.1M
YoY Change	-20.3%	119.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.689M	$1.301M
YoY Change	106.69%	14.73%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$2.000M
YoY Change
Other Assets	$1.464M	$1.600M
YoY Change	-8.5%	14.29%
Total Long-Term Assets	$15.69M	$13.62M
YoY Change	15.18%	-5.15%
TOTAL ASSETS
Total Short-Term Assets	$130.0M	$163.1M
Total Long-Term Assets	$15.69M	$13.62M
Total Assets	$145.7M	$176.7M
YoY Change	-17.57%	99.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$264.0K	$594.0K
YoY Change	-55.56%	-55.34%
Accrued Expenses	$8.889M	$6.847M
YoY Change	29.82%	-21.97%
Deferred Revenue	$27.99M	$75.76M
YoY Change	-63.06%	4425.93%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$696.0K	$500.0K
YoY Change	39.2%	-97.04%
Total Short-Term Liabilities	$39.25M	$84.61M
YoY Change	-53.61%	181.35%
LONG-TERM LIABILITIES
Long-Term Debt	$25.04M	$24.60M
YoY Change	1.8%
Other Long-Term Liabilities	$25.64M	$87.20M
YoY Change	-70.59%	29.19%
Total Long-Term Liabilities	$50.69M	$111.8M
YoY Change	-54.66%	65.63%
TOTAL LIABILITIES
Total Short-Term Liabilities	$39.25M	$84.61M
Total Long-Term Liabilities	$50.69M	$111.8M
Total Liabilities	$89.93M	$196.3M
YoY Change	-54.19%	101.22%
SHAREHOLDERS EQUITY
Retained Earnings	-$401.5M	-$429.2M
YoY Change	-6.45%	20.77%
Common Stock	$12.00K	$11.00K
YoY Change	9.09%	22.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$55.76M	-$19.57M
YoY Change
Total Liabilities & Shareholders Equity	$145.7M	$176.7M
YoY Change	-17.57%	99.04%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	$28.78M	-$24.60M
YoY Change	-217.0%	25.37%
Depreciation, Depletion And Amortization	$100.0K	$100.0K
YoY Change	0.0%	-50.0%
Cash From Operating Activities	-$11.86M	-$12.13M
YoY Change	-2.22%	3.72%
INVESTING ACTIVITIES
Capital Expenditures	$455.0K	$25.00K
YoY Change	1720.0%	-81.48%
Acquisitions
YoY Change
Other Investing Activities	$10.00M	-$22.42M
YoY Change	-144.6%
Cash From Investing Activities	$9.545M	-$22.45M
YoY Change	-142.53%	16525.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$1.690M	$20.99M
YoY Change	-91.95%	1739.7%
Debt Paid & Issued, Net		$0.00
YoY Change		-100.0%
Cash From Financing Activities	$1.728M	$21.31M
YoY Change	-91.89%	-496.78%
NET CHANGE
Cash From Operating Activities	-$11.86M	-$12.13M
Cash From Investing Activities	$9.545M	-$22.45M
Cash From Financing Activities	$1.728M	$21.31M
Net Change In Cash	-$620.0K	-$13.28M
YoY Change	-95.33%	-23.19%
FREE CASH FLOW
Cash From Operating Activities	-$11.86M	-$12.13M
Capital Expenditures	$455.0K	$25.00K
Free Cash Flow	-$12.32M	-$12.16M
YoY Change	1.32%	2.75%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001453687
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-37798
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	Selecta Biosciences, Inc
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1622110
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	65 Grove Street,
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Watertown,
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02472
CY2022Q1	dei	City Area Code CityAreaCode	617
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	923-1400
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2022Q1	dei	Trading Symbol TradingSymbol	SELB
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	151809416	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	113437000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	114057000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	3997000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	13998000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7153000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9914000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5420000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6474000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	130007000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	144443000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2689000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2142000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9536000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9829000	USD
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1379000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1379000	USD
CY2022Q1	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	2000000	USD
CY2021Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	2000000	USD
CY2022Q1	us-gaap	Other Assets OtherAssets	85000	USD
CY2021Q4	us-gaap	Other Assets OtherAssets	90000	USD
CY2022Q1	us-gaap	Assets Assets	145696000	USD
CY2021Q4	us-gaap	Assets Assets	159883000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	264000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	224000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8889000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10533000	USD
CY2022Q1	us-gaap	Loans Payable Current LoansPayableCurrent	696000	USD
CY2021Q4	us-gaap	Loans Payable Current LoansPayableCurrent	5961000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1087000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1049000	USD
CY2022Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	320000	USD
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	601000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	27990000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	53883000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	39246000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	72251000	USD
CY2022Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	25042000	USD
CY2021Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	19673000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8316000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8598000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	10420000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	11417000	USD
CY2022Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	6908000	USD
CY2021Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	25423000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	89932000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	137362000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	124380844	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	124380844	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	123622965	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	123622965	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	12000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	12000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	461888000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	457391000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-401538000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-430316000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4598000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4566000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	55764000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	22521000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	145696000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	159883000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	33999000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11050000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17689000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13004000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5537000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5204000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	23226000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	18208000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	10773000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7158000	USD
CY2022Q1	us-gaap	Investment Income Net InvestmentIncomeNet	15000	USD
CY2021Q1	us-gaap	Investment Income Net InvestmentIncomeNet	12000	USD
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	28000	USD
CY2021Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	7000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	707000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	711000	USD
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-18515000	USD
CY2021Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	16747000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	154000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	28778000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-24597000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-32000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-6000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	28746000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24604000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.23
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.08
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	124232799	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	110742150	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	127573485	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	110742150	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	22521000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	127000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	21000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	1675000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-79000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2753000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-32000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	28778000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	55764000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-18006000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	72000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	244000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	20943000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1780000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-6000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-24597000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-19571000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	28778000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-24597000	USD
CY2022Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	351000	USD
CY2021Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	207000	USD
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1000	USD
CY2021Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-14000	USD
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	293000	USD
CY2021Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	272000	USD
CY2022Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	147000	USD
CY2021Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2753000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1780000	USD
CY2022Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	383000	USD
CY2021Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	387000	USD
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-18515000	USD
CY2021Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	16747000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2761000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1118000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-853000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1512000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	18000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	151000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-281000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0	USD
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-26890000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2728000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2222000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1736000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11864000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12133000	USD
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	10000000	USD
CY2021Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0	USD
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	USD
CY2021Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	22420000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	455000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	25000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9545000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22445000	USD
CY2022Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	110000	USD
CY2021Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1690000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20991000	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	21000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	244000	USD
CY2022Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	127000	USD
CY2021Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	72000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1728000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21307000	USD
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-29000	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-7000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-620000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-13278000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115436000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	140064000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	114816000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	126786000	USD
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	494000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	494000	USD
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	91000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	10000	USD
CY2022Q1	selb	Equity Offering Costs In Accrued Liabilities EquityOfferingCostsInAccruedLiabilities	94000	USD
CY2021Q1	selb	Equity Offering Costs In Accrued Liabilities EquityOfferingCostsInAccruedLiabilities	48000	USD
CY2022Q1	selb	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Debt Securities Available For Sale CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale	118800000	USD
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1400000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	3997000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	3997000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	13999000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	13998000	USD
CY2022Q1	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	28778000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-24597000	USD
CY2022Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	18515000	USD
CY2021Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	10263000	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	10263000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24597000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-24597000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	124232799	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	110742150	shares
CY2022Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	3340686	shares
CY2021Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	127573485	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	110742150	shares
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.23
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.08
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15585436	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23242827	shares
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	0	USD
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet	0	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	113437000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	125407000	USD
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1379000	USD
CY2021Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1379000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	114816000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	126786000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7350000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6939000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4661000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4797000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2689000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2142000	USD
CY2022Q1	us-gaap	Depreciation Depreciation	100000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	100000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1116000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3179000	USD
CY2022Q1	selb	Accrued Patent Fees Current AccruedPatentFeesCurrent	711000	USD
CY2021Q4	selb	Accrued Patent Fees Current AccruedPatentFeesCurrent	309000	USD
CY2022Q1	selb	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	4973000	USD
CY2021Q4	selb	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	4339000	USD
CY2022Q1	selb	Accrued Audit Fees Current AccruedAuditFeesCurrent	1560000	USD
CY2021Q4	selb	Accrued Audit Fees Current AccruedAuditFeesCurrent	815000	USD
CY2022Q1	selb	Accrued Interest Current AccruedInterestCurrent	179000	USD
CY2021Q4	selb	Accrued Interest Current AccruedInterestCurrent	170000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	350000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1721000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8889000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10533000	USD
CY2021Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	900000	USD
CY2022Q1	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	900000	USD
CY2021	us-gaap	Loss Contingency Claims Settled Number LossContingencyClaimsSettledNumber	2	lawsuit
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	506000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	444000	USD
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	220000	USD
CY2021Q1	us-gaap	Variable Lease Cost VariableLeaseCost	288000	USD
CY2022Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	3000	USD
CY2021Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	3000	USD
CY2022Q1	us-gaap	Lease Cost LeaseCost	729000	USD
CY2021Q1	us-gaap	Lease Cost LeaseCost	735000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1409000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1922000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1980000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2039000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2101000	USD
CY2022Q1	selb	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	2844000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	12295000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2892000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	9403000	USD
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	457000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	444000	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y1M6D
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y1M6D
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.089
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.089
CY2022Q1	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	900000	USD
CY2022Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10735980	shares
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.62
CY2022Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	34210815	shares
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	28209867	shares
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2753000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1780000	USD
CY2022Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	38400000	USD
CY2021Q4	selb	Contractwith Customer Liability Deferred Revenue ContractwithCustomerLiabilityDeferredRevenue	65300000	USD
CY2022Q1	selb	Contractwith Customer Liability Deferred Revenue Increase From Cash Receipts ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts	0	USD
CY2022Q1	selb	Contractwith Customer Liability Deferred Revenue Revenue Recognized ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized	26890000	USD
CY2022Q1	selb	Contractwith Customer Liability Deferred Revenue ContractwithCustomerLiabilityDeferredRevenue	38410000	USD
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	65300000	USD
CY2022Q1	selb	Contractwith Customer Liability Increase From Cash Receipts ContractwithCustomerLiabilityIncreaseFromCashReceipts	0	USD
CY2022Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	26890000	USD
CY2022Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	38410000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	51100000	USD
CY2022Q1	selb	Defined Contribution Plan Employers Matching Contribution Vesting Period DefinedContributionPlanEmployersMatchingContributionVestingPeriod	P2Y
CY2022Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	USD
CY2021Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	USD

Files In Submission

Name	View Source	Status
0001453687-22-000087-index-headers.html	Edgar Link	pending
0001453687-22-000087-index.html	Edgar Link	pending
0001453687-22-000087.txt	Edgar Link	pending
0001453687-22-000087-xbrl.zip	Edgar Link	pending
exhibit311_03312022.htm	Edgar Link	pending
exhibit312_03312022.htm	Edgar Link	pending
exhibit321_03312022.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
selb-20220331.htm	Edgar Link	pending
selb-20220331.xsd	Edgar Link	pending
selb-20220331_cal.xml	Edgar Link	unprocessable
selb-20220331_def.xml	Edgar Link	unprocessable
selb-20220331_htm.xml	Edgar Link	completed
selb-20220331_lab.xml	Edgar Link	unprocessable
selb-20220331_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RNAC
Cartesian Therapeutics, Inc. Stock $rnac

2022 Q1 Form 10-Q Financial Statement

#000145368722000087 Filed on May 05, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNAC Cartesian Therapeutics, Inc. Stock $rnac

2022 Q1 Form 10-Q Financial Statement

#000145368722000087 Filed on May 05, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNAC
Cartesian Therapeutics, Inc. Stock $rnac